TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) Research & Development (2020 - 2026)

Updated

TScan Therapeutics (TCRX) reported Research & Development of $25.29 million for Q3 2026, down 20.2% from $31.69 million a year earlier but up 8.1% from the prior quarter.

Analysis

TScan Therapeutics (TCRX) Research & Development (2020 - 2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, TScan Therapeutics' Research & Development came in at $90.64 million, down 26.6% year-over-year; for FY2025, it came in at $114.15 million, up 6.3% from FY2024.

  • Research & Development has increased for five consecutive years, with a five-year compound annual growth rate of 40.9% (FY2020 to FY2025).
  • By year, Research & Development came in at $107.35 million in FY2024 (+21.8%), $88.15 million in FY2023 (+47.4%), $59.82 million in FY2022 (+33.1%) and $44.95 million in FY2021 (+118.5%).
  • Five-year quarterly Research & Development spans a low of $12.61 million in Q4 2021 and a high of $32.63 million in Q2 2025.
  • Year over year, Research & Development has now declined in each of the last four quarters, with an average decline of 1.7% over the last eight quarters.
  • The high point for year-over-year Research & Development in five years was Q4 2021 (growth of 111.4%); the low point was Q4 2025 (a decline of 31.7%).
  • Per Business Quant data, the three quarters before Q3 2026 came in at $23.4 million (Q2 2026), $21.9 million (Q1 2026) and $20.04 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 322,296.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 4.25 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 4.65 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 2.57 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 4.54 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 1.61 Bn
9 Gsk 193.54 Bn 176.38 Bn - -
10 TScan Therapeutics 18.87 Mn -434.83 Mn - 25.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 25.29 Mn
Jun 30, 2026 23.40 Mn
Mar 31, 2026 21.90 Mn
Dec 31, 2025 20.04 Mn
Sep 30, 2025 31.69 Mn
Jun 30, 2025 32.63 Mn
Mar 31, 2025 29.79 Mn
Dec 31, 2024 29.35 Mn
Sep 30, 2024 26.26 Mn
Jun 30, 2024 26.88 Mn
Mar 31, 2024 24.86 Mn
Dec 31, 2023 22.41 Mn
Sep 30, 2023 22.74 Mn
Jun 30, 2023 21.23 Mn
Mar 31, 2023 21.78 Mn
Dec 31, 2022 15.60 Mn
Sep 30, 2022 15.03 Mn
Jun 30, 2022 14.49 Mn
Mar 31, 2022 14.69 Mn
Dec 31, 2021 12.61 Mn
API Access

TScan Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=TCRX&period=max&api_key=YOUR_API_KEY